Overview

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness

Status:
Active, not recruiting

Trial end date:
2021-12-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Collaborators:

AbCellera Biologics Inc.
Shanghai Junshi Bioscience Co., Ltd.